• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Progenics Pharmaceuticals

Progenics Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. It’s Never Too Early: Roth 401(k)s and Other Fun Stuff

    Progenics Pharmaceuticals PGNX announced on March 6 that it would backtrack and reformulate the oral version opioid bowel dysfunction drug MNTX to make it more effective. If successful, the firm could file for its approval in late 2009. Our fair value estimate remains unchanged, as we'd already ...

  2. Investor or Speculator?

    Progenics Pharmaceuticals PGNX and partner Wyeth WYE announced Thursday that both the Food and Drug Administration and the European Medicines Agency have accepted new drug applications for subcutaneous MNTX, which aims to treat postoperative ileus and opioid bowel dysfunction. We are leaving our ...

  3. Chi-Med appoints Industry Veteran Karen Ferrante to Board of Directors

    Chi-Med appoints Industry Veteran Karen Ferrante to Board of Directors

©2017 Morningstar Advisor. All right reserved.